José Ignacio Herrero Santos-rekin lankidetzan egindako argitalpenak (9)

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study

    Liver Transplantation, Vol. 23, Núm. 5, pp. 645-651

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation

    Transplantation, Vol. 100, Núm. 3, pp. 593-599

2015

  1. Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients

    Clinical Transplantation, Vol. 29, Núm. 8, pp. 667-677

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

2014

  1. "very early" intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?

    American Journal of Transplantation, Vol. 14, Núm. 3, pp. 660-667

  2. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A spanish matched cohort multicenter study

    Annals of Surgery, Vol. 259, Núm. 5, pp. 944-952

2008

  1. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: Results of a prospective randomized study

    Liver Transplantation, Vol. 14, Núm. 12, pp. 1752-1760